Active Immunization for Unconventional Indications Report

Description: The aim of this report is to provide information about vaccines in development for unconventional indications and non-infectious diseases. Further focus will be placed on sophisticated antigen(s)-specific vaccines and vaccines where induced polyclonal antibodies are claimed to be the main mode of action. The scope of this report does not include vaccines against microorganisms which are used for non-infectious diseases (e.g., cancer vaccines targeting HPV). Also, the term “vaccine” as used in this report does not mean a monoclonal antibody (mAb) or immunoglobulin (IgGs) infusion.

Rather than explaining the background behind immune reactions a comparative overview will be made of active candidates with details on indications, targets, stage of development, technologies, and the companies supporting them. Target product profiles will be provided for the most advanced candidates and details on single vaccines will also be provided for other vaccines in active development.

Most of the vaccines here will be synthetic vaccines generally composed of a synthetic B-cell epitope(s), usually coupled to a carrier in order to introduce T-cell epitopes necessary for inducing a correct and complete immune response and an adjuvant for amplifying immune response. This view is of course very simplified and details about vaccine composition will be discussed for the individual vaccines.

“Pure” T-cell vaccines (where the main mode of action is mediated by T lymphocytes) have not been included. However, some of the vaccines included report both modes of action equally and the importance of each is still to be elucidated.

Reference is also made to “Selected special antibody-inducing vaccines” which are interesting from a technological and conceptual point of view although they do not strictly fall into above mentioned scope of this review. There is a potential that these vaccines or the technologies behind them will be used more generally in the future, once they have been further elucidated, defined, and developed.

The scope of the current report includes more than 100 active vaccine projects. Basic information is also given on dozens of stopped projects. A single vaccine project means a vaccine used for a single indication. Some vaccines (same formulation) are developed for more than one indication. Also, when a new formulation is disclosed, this is counted as a new vaccine.

Contents:

1. Aim and Scope
2. Introduction
3. Indications
4. Targets
5. Most advanced vaccines (Phase III-Phase I/II)
   5.1. Overview
   5.2. Target product profiles (TPPs)
6. Phase I vaccines
   6.1. Overview
   6.2. Details on Phase I vaccines
7. Preclinical candidates
   7.1. Overview
   7.2. Details on vaccines in preclinical development
8. Most active players in the field
9. Stopped vaccines
List of Tables:
Table 1 List of vaccines for cancer indications
Table 2 List of vaccines for neurodegenerative diseases
Table 3 List of vaccines for allergies
Table 4 List of vaccines for addictions
Table 5 List of vaccines for cardiovascular diseases
Table 6 List of vaccines for autoimmune disorders
Table 7 List of most frequent targets used for vaccines development
Table 8 TPP of Vaccine 1
Table 9 TPP of Vaccine 2
Table 10 TPP of Vaccine 3
Table 11 TPP of Vaccine 4
Table 12 TPP of Vaccine 5
Table 13 TPP of Vaccine 6
Table 14 TPP of Vaccine 7
Table 15 TPP of Vaccine 8
Table 16 TPP of Vaccine 9
Table 17 TPP of Vaccine 10
Table 18 TPP of Vaccine 11
Table 19 TPP of Vaccine 12
Table 20 TPP of Vaccine 13
Table 21 TPP of Vaccine 14
Table 22 TPP of Vaccine 15
Table 23 TPP of Vaccine 16
Table 24 TPP of Vaccine 17
Table 25 TPP of Vaccine 18
Table 26 TPP of Vaccine 19
Table 27 TPP of Vaccine 20
Table 28 TPP of Vaccine 21
Table 29 TPP of Vaccine 22
Table 30 TPP of Vaccine 23
Table 31 TPP of Vaccine 24
Table 32 TPP of Vaccine 25
Table 33 TPP of a recently discontinued vaccine
Table 34 List of Phase I vaccines
Table 35 TPP of Vaccine 26
Table 36 TPP of Vaccine 27
Table 37 TPP of Vaccine 28
Table 38 TPP of Vaccine 29
Table 39 TPP of Vaccine 30
Table 40 TPP of Vaccine 31
Table 41 TPP of Vaccine 32
Table 42 TPP of Vaccine 33
Table 43 TPP of Vaccine 34
Table 44 TPP of Vaccine 35
Table 45 TPP of Vaccine 36
Table 46 TPP of Vaccine 37
Table 47 TPP of Vaccine 38
Table 48 TPP of Vaccine 39
Table 49 TPP of Vaccine 40
Table 50 TPP of Vaccine 41
Table 51 TPP of Vaccine 42
Table 52 TPP of Vaccine 43
Table 53 TPP of Vaccine 44
Table 54 TPP of Vaccine 45
Table 55 TPP of Vaccine 46
Table 56 TPP of Vaccine 47
Table 57 TPP of Vaccine 48
Table 58 TPP of Vaccine 49
Table 59 TPP of Vaccine 50
Table 60 TPP of Vaccine 51
Table 61 TPP of Vaccine 52
Table 62 TPP of Vaccine 53
Table 63 TPP of Vaccine 54
Table 64 TPP of Vaccine 55
Table 65 TPP of Vaccine 56
Table 66 TPP of Vaccine 57
Table 67 List of vaccines in preclinical development
Table 68 TPP of Vaccine 58
Table 69 TPP of Vaccine 59
Table 70 TPP of Vaccine 60
Table 71 TPP of Vaccine 61
Table 72 TPP of Vaccine 62
Table 73 TPP of Vaccine 63
Table 74 TPP of Vaccine 64
Table 75 TPP of Vaccine 65
Table 76 TPP of Vaccine 66
Table 77 TPP of Vaccine 67
Table 78 TPP of Vaccine 68
Table 79 TPP of Vaccine 69
Table 80 TPP of Vaccine 70
Table 81 TPP of Vaccine 71
Table 82 TPP of Vaccine 72
Table 83 TPP of Vaccine 73
Table 84 TPP of Vaccine 74
Table 85 TPP of Vaccine 75
Table 86 TPP of Vaccine 76
Table 87 TPP of Vaccine 77
Table 88 TPP of Vaccine 78
Table 89 TPP of Vaccine 79
Table 90 TPP of Vaccine 80
Table 91 TPP of Vaccine 81
Table 92 TPP of Vaccine 82
Table 93 TPP of Vaccine 83
Table 94 TPP of Vaccine 84
Table 95 TPP of Vaccine 85
Table 96 TPP of Vaccine 86
Table 97 TPP of Vaccine 87
Table 98 TPP of Vaccine 88
Table 99 TPP of Vaccine 89
Table 100 TPP of Vaccine 90
Table 101 TPP of Vaccine 91
Table 102 TPP of Vaccine 92
Table 103 TPP of Vaccine 93
Table 104 TPP of Vaccine 94
Table 105 TPP of Vaccine 95
Table 106 TPP of Vaccine 96
Table 107 TPP of Vaccine 97
Table 108 TPP of Vaccine 98
Table 109 TPP of Vaccine 99
Table 110 TPP of Vaccine 100
Table 111 TPP of Vaccine 101
Table 112 TPP of Vaccine 102
Table 113 TPP of Vaccine 103
Table 114 TPP of Vaccine 104
Table 115 TPP of Vaccine 105
Table 116 TPP of Vaccine 106
Table 117 Selection of stopped vaccines

List of Figures:
Figure 1 Overview of active and inactive/unknown status vaccines according to therapeutic area
Figure 2 Most advanced vaccines timelines

Ordering: Order Online - http://www.researchandmarkets.com/reports/3704644/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Active Immunization for Unconventional Indications Report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3704644/">http://www.researchandmarkets.com/reports/3704644/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6I5R4T</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Product Format</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) - Single User</td>
<td>USD 1028</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 2970</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Email Address:</td>
<td>* ____________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>____________________________</td>
</tr>
<tr>
<td>City:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>____________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World